Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0USILO
ADC Name
TAC-001
Synonyms
TAAC-001; TAC 001; CD22 targeting TRAAC-Tallac Therapeutics
   Click to Show/Hide
Organization
Tallac Therapeutics, Inc.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
Antibody Name
Undisclosed
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
Differentiated TLR-9 agonist (T-CpG)
  Payload Info 
Therapeutic Target
Toll-like receptor 9 (TLR9)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05399654
Phase 1/2
A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05399654  Clinical Status Phase 1/2
Clinical Description A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
References
Ref 1 A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors, NCT05399654

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.